← SynDRA
BEMCENTINIB
SynDRA canonical compound SYN0038561 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AXL |
|---|
| Mechanism of action | AXL kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AXL kinase inhibitor
- AXL INHIBITOR
- Tyrosine-protein kinase receptor UFO inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- KDR
- KIT
- SRC
- RET
- PDGFRA
- MET
- MERTK
- TYRO3
- FLT3
- EGFR
- DDR1
- AURKB
- AURKA
- ALK
- HDAC6
- AKT1
- MTOR
- ABL1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2D6
- GAMT
- GNMT
- HNMT
- IFNG
- JAK2
- KSYK
- NNMT
- NSD2
- NTM1A
- NTMT1
- PNMT
- SYK
Cross-references
Synonyms
- BGB-324
- BGB324
- CS-1046
- HY-15150
- KB-80319
- QC-11751
- R-428
- R428
- SYN-1131
- SYN1131
- W-5845
- R 428
- UNII-0ICW2LX8AS
- (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine
- CHEMBL3809489
- Bemcentinib [USAN]
- R428 (BGB324)
- Bemcentinib (USAN/INN)
- BemcentinibR428BGB324)
- SCHEMBL1639904
- GTPL10478
- DTXSID70673109
- 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
- AMY16774
- BCP21180
- C30H34N8
- EX-A1720
- BDBM50172079
- NSC824183
- s2841
- WHO 10631
- ZINC51951669
- AKOS032947237
- ACN-037541
- DB12411
- NSC-824183
- SB16614
- NCGC00386665-07
- 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine
Look up BEMCENTINIB in the interactive SynDRA portal →